

# Management and Treatment of Dementia

**Charles T Nevels, MD**

---

---

---

---

---

---

---

---

## Incidence of Neurocognitive disorders

- 1 in 9 individuals over 65 years of age have dementia
- 1 person develops dementia every 67 seconds in the United States
- Incidence of dementia almost doubles with every 5 year increase in age of a cohort.
- Per 2019 CDC/CMS data 58.9% of all (long term) SNF patients have dementia
- More recent data shows the percentage increasing to near 60%.
- 2019 CDC/CMS data shows 53% of all SNF patients have depression
- Researchers examined data on more than 3.7 million admissions to 15,600 facilities nationwide from 2012 to 2014. Even after excluding dementia and Alzheimer's disease, which are a common causes of nursing home admissions, people with behavioral health issues account for about half of all residents, researchers note in the *American Journal of Geriatric Psychiatry*, 2018. With behavioral health problems, patients were also more likely to be sent to one-star homes, the lowest quality facilities, the study also found.

---

---

---

---

---

---

---

---

## Prevalence of Alzheimer's Dementia in USA

- Ages 40-65 1 in 1000
- Ages 65-74 3%
- Ages 75-84 17%
- Age 85+ 32%

Prevalence of Dementia, NOS Ages 71 Y/O and up approx. 14%  
With similar increase with age...

---

---

---

---

---

---

---

---

## Risk Factors for Dementia

- Gender: male
- Age: 60-70 years
- Prior stroke
- Hardening of the arteries
- Heart disease
- High blood pressure
- Diabetes
- Cholesterol problems
- Atrial fibrillation
- Smoking
- Education
- Race
- Family history

---

---

---

---

---

---

---

---



FIG. 4. In the laboratory of the neurology clinic, Munich: 1, F. Letmar; 2, Frau Grombach; 3, St. Rosenthal; 4, Ugo Cerletti; 5, Allers(?); 6, F. Bonfiglio; 7, A. Alzheimer; 8, N. Achucarro; 9, G. Perusini; 10, F. H. Lewy.

A picture of Alois Alzheimer and his co-workers in which Friedrich Lewy is standing to the very right side of the picture

---

---

---

---

---

---

---

---

In 1906, the German psychiatrist and neurologist Dr Alois **Alzheimer** first identified the illness that would become known as **Alzheimer's disease**. His discovery was based on the case of a 51-year-old woman, Auguste Deter, who had suddenly begun to exhibit irrational behaviour and memory loss.




---

---

---

---

---

---

---

---

## Etiologic Diagnosis of Progressive Dementias in Adults

### • Neurodegenerative Diseases

- Alzheimer's disease
- Parkinson's disease
- Diffuse Lewy body disease
- Progressive supranuclear palsy
- Multisystem atrophy
- Huntington's disease
- Frontotemporal dementias – e.g. Pick's disease

---

---

---

---

---

---

---

---

## Etiology *contd.*

### • Structural Disease or Trauma

- Normal pressure hydrocephalus
- Neoplasms
- Dementia pugilistica

### • Vascular Disease

- Vascular dementia
- Vasculitis

### • Heredometabolic Disease

- Wilson's disease
- Other late-onset lysosomal storage diseases

---

---

---

---

---

---

---

---

## Etiology *contd.*

### • Demyelinating or Dysmyelinating Disease

- Multiple sclerosis

### • Infectious Disease

- Human immunodeficiency virus, type 1
- Tertiary syphilis
- Creutzfeldt-Jakob disease
- Progressive multifocal leukoencephalopathy
- Whipple's disease
- Chronic meningitis – e.g. Cryptococcal

---

---

---

---

---

---

---

---




---

---

---

---

---

---

---

---

### Memory in typical aging

- Myth: "Forgetfulness" is an inevitable consequence of aging.
- Typical aging per se does not degrade memory - - - disease does.
- Everyday forgetfulness occurs in most
  - Easy to overlook genuine memory lapses in dementia
  - Misleads people with normal brain function who fear development of AD

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

## Signs and Symptoms of AD

Mild AD	Moderate AD	Severe AD
<ul style="list-style-type: none"> <li>• Forgetfulness</li> <li>• Word finding difficulty</li> <li>• Apathy</li> <li>• Poor attention</li> <li>• Difficulty with complex tasks</li> <li>• Depression</li> <li>• Work trouble</li> </ul>	<ul style="list-style-type: none"> <li>• Disorientation</li> <li>• ↑ memory loss</li> <li>• Confusion</li> <li>• Insomnia</li> <li>• Wandering</li> <li>• Speech difficulty</li> <li>• Restlessness</li> <li>• Difficulty with IADLs</li> </ul>	<ul style="list-style-type: none"> <li>• Agnosia</li> <li>• Apraxia</li> <li>• Aggression</li> <li>• Agitation</li> <li>• Incontinence</li> <li>• Poor basic ADLs</li> <li>• Gait disturbance</li> </ul>

IADL: instrumental activities of daily living  
ADL: activities of daily living

---

---

---

---

---

---

---

---

## Diagnostic Criteria for Dementia

- Presence of at least 2 of the following impairments.
  - Impaired learning and impaired retention of new or recently acquired information (**short-term memory**)
  - Impaired handling of complex tasks
  - Impaired reasoning ability (**Abstract thinking**)
  - Impaired spatial ability and orientation (**constructional difficulty and agnosia**)
- The impairments interfere with work or usual social activities or relationships with others
- The impairments represent a notable decline from a previous level of functioning
- The impairments do not occur exclusively during the course of delirium
- The impairments are not better explained by a major psychiatric diagnosis

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

---

---

---

---

## Mini-Mental State Examination (MMSE)

- Cognitive measurement
- Brief, structured mental status examination
- 10-15 minutes to administer
- Adjustments need to be made for age, gender, education, and culture
- Copyright issues

Scores Range From 0-30

28-30=Normal  
25-27=Mild cognitive impairment  
19-24=Mild dementia  
10-18=Moderate dementia  
0-9=Severe dementia

Typical deterioration of  
3-4 points per year

Folstein MF, et al. J Psychiatr Res. 1975;12(12):129-138

### Mini-Mental State Examination (MMSE)

Maximum Score	Patients Score	Questions
5		"What is the year? (month/year)?" (month/year)
5		"What day of the week is it today?" (day of the week)
3		The examiner names three unrelated objects clearly and slowly. Then the instruction asks the patient to name all three of them. The patient's response is used for scoring. The examiner repeats these with patient names all of them, if possible.
5		"I would like you to count backwards from 100 by sevens." (93, 86, 79, 72, 65, ...)
3		"Spell the word 'WORLD' backwards." (D, L, R, O, R, L)
3		"Spell the word 'WORLD' backwards." (D, L, R, O, R, L)
2		"Draw the patient two simple objects, such as a watchface and a pencil, and ask the patient to name them.
1		"Repeat the phrase: 'No ifs, ands, or buts.'"
3		"Take the paper in your right hand, fold it in half, and put it on the floor." (The examiner gives the patient a piece of blank paper.)
1		"Place your fist and do what I say." (Written instruction to "Place your fist.")
1		"Write up and write a sentence about anything." (This sentence must contain a noun and a verb.)
1		"Place copy the picture." (The examiner shows the patient a blank piece of paper and asks them to draw the picture below. All 13 angles must be present and two must be correct.)
30		Total

### Interpretation of the MMSE

Measure	Score	Interpretation
Single word	<24	Abnormal
Range	<21	Increased risk of dementia
	<18	Decreased risk of dementia
Education	<21	Abnormal for 0-6 grade education
	<23	Abnormal for high school education
	<24	Abnormal for college education
Severity	18-24	Mild cognitive impairment
	10-23	Moderate cognitive impairment
	0-9	Severe cognitive impairment

### Interpretation of MMSE Scores

Score	Degree of Impairment	Formal Psychiatric Assessment	Day-to-Day Functioning
24-30	Normal	Formal psychiatric assessment not needed. Formal assessment of cognition may be indicated.	No formal assessment required but some deficits may be present only in formal testing situations.
21-23	Mild	Formal assessment may be indicated to confirm diagnosis and extent of deficits.	Significant deficits may impact social, occupational, and instrumental activities.
18-20	Moderate	Formal assessment and treatment of deficits are indicated.	Clear impairment. May require formal psychiatric assessment.
10-17	Severe	Formal assessment and treatment of deficits are indicated.	Marked impairment. May require formal psychiatric assessment and treatment.

### Source:

Folstein MF, Folstein SE, McHugh PR. "The 'mini-mental state': A practical method for grading the clinician." J Psychiatr Res 1975;12:129-138.

---

---

---

---

---

---

---

---

---

---

---

---



Patient name: \_\_\_\_\_  
 Testing date: \_\_\_\_\_

**STEP 2: INFORMANT INTERVIEW**

Informant name: \_\_\_\_\_  
 Relationship to patient, i.e. Informant is the patient's: \_\_\_\_\_

Ask the informant:

Compared to 5–10 years ago:

	Yes	No	Don't know	NA
1. Does the patient have more trouble remembering things that have happened recently than when used to?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Does s/he have more trouble recalling conversations in the days past?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. When speaking, does s/he have more difficulty in finding the right word or word to use the wrong words more often?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Is s/he less able to manage money and financial affairs (e.g. paying bills and budgeting)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Is s/he less able to manage his or her medication independently?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Does s/he need more assistance with transport (either driver or passenger)? <small>(If the patient has difficulties only due to physical problems, e.g. bad leg, etc. 'No')</small>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Add the number of items answered 'Yes', 'Don't know' or 'No': \_\_\_\_\_

Total score: \_\_\_\_\_ out of 6

4–6: No significant cognitive impairment  
 Further testing not necessary.  
 0–3: Cognitive impairment is indicated.  
 Conduct additional investigations.

When referring to a specialist, mention the individual scores for the two CPOG test steps:

STEP 1: Patient examination: \_\_\_\_\_ of 9

STEP 2: Informant interview: \_\_\_\_\_ of 6 or NA

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

## BPSD

- Behavioral and psychological symptoms of dementia (BPSD), also known as neuropsychiatric symptoms, represent a heterogeneous group of non-cognitive symptoms and behaviors occurring in subjects with dementia. BPSD constitute a major component of the dementia syndrome irrespective of its subtype. They are as clinically relevant as cognitive symptoms as they strongly correlate with the degree of functional and cognitive impairment. BPSD include agitation, aberrant motor behavior, anxiety, elation, irritability, depression, apathy, disinhibition, delusions, hallucinations, and sleep or appetite changes. It is estimated that BPSD affect up to 90% of all dementia subjects over the course of their illness, and is independently associated with poor outcomes, including distress among patients and caregivers, long-term hospitalization, misuse of medication, and increased health care costs. Although these symptoms can be present individually it is more common that various psychopathological features co-occur simultaneously in the same patient. Thus, categorization of BPSD in clusters taking into account their natural course, prognosis, and treatment response may be useful in the clinical practice.

---

---

---

---

---

---

---

---

## What are "Behaviors?"

- Apathy, depression, anxiety and agitation were found to be the most frequent forms of BPSD.
- Delusions (distressing beliefs) Hallucination
- Agitation: – Easily upset – Repeating questions – Arguing/complaining- Pacing
- Hoarding
- Refusing care: -eating – bathing – meds- ADLs
- Inappropriate screaming, crying out, disruptive sounds
- Leaving home, attempting to leave/exit seeking
- Depression or dysphoria Anxiety: – Worrying – Shadowing (following care giver)
- Apathy or indifference Disinhibition: – Socially inappropriate behavior – Sexually inappropriate behavior
- Irritability or lability Motor disturbance (repetitive activities without purpose): – Wandering – Rummaging Night-time behaviors (waking and getting up at night)

---

---

---

---


---

---

---


---

## Neuropsychiatric Symptoms in Dementias




Neuropsychiatric symptoms in dementia: (1) Frontotemporal dementia, (2) Dementia with Lewy bodies, (3) Alzheimer's disease, (4) Vascular dementia, (5) Mixed dementia, (6) Dementia with mixed pathology. AD, Alzheimer's disease; PDD, Parkinson's disease dementia; DLB, Dementia with Lewy bodies; VaD, Vascular dementia; FTD, Frontotemporal dementia. ●, 15-29%; ●●, 30-44%; ●●●, 45-59%; ●●●●, ≥60%. —, 0-14%. Adapted from: Aarsland D, Larsen J, Dawson VL, Dawson TM, et al. J Neurol Neurosurg Psychiatry. 2005;76(11):1181-1186. Copyright 2005 British Medical Association. All rights reserved.

## Timeline and Epidemiology of Psychiatric Symptoms in AD



## Dementia: Behavioral Symptoms Worsen as Cognition Declines<sup>1</sup>



Dementia patients who display marked behavioral disturbances in a given time frame are more likely to display them again in the future.<sup>1</sup>

1. Rabins PV, et al. Am J Psychiatry. 2007;164(12):1665-1672. Copyright 2007 American Psychiatric Association. All rights reserved.

### Symptom Clusters

- Apathy, depression, anxiety and agitation were found to be the most frequent forms of BPSD.
- BPSD tends to cluster together, usually into four clusters – that is, the affective, psychotic, hyperactive and apathetic clusters.
- **Pre-existing personality and psychiatric illnesses** Clinical experience suggests that longstanding personality patterns and characteristics may affect the development of behavioral and psychological symptoms of dementia—the loss of inhibitory control may accentuate premorbid personality traits. Lifelong psychiatric disorders (such as major depression, anxiety, bipolar disorder, and schizophrenia) and their management (for example, treatment with antidepressants, anxiolytics, mood stabilizers, and antipsychotics) may also affect the development of these symptoms.

---

---

---

---

---

---

---

---

### Pharmacological Management

(to give nonpharmacological treatment a better chance of success)

- 1) Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for cognition in mild to moderate Alzheimer's disease (A).
- 2) Memantine for moderate to severe Alzheimer's disease (A) and combination therapy (cholinesterase inhibitors and memantine) may be beneficial (B). Drugs should not be stopped just because dementia severity increases (A).
- 3) Neither cholinesterase inhibitors nor memantine are effective in those with mild cognitive impairment (A).
- 4) Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioral (but not cognitive) features (B).
- 5) Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (both Parkinson's disease dementia and dementia with Lewy bodies), and memantine may be helpful (A).

---

---

---

---

---

---

---

---

- 6) No drugs are clearly effective in vascular dementia, though cholinesterase inhibitors are beneficial in mixed dementia (B).
  - 7) Early evidence suggests multifactorial interventions may have potential to prevent or delay the onset of dementia (B).
  - 8) Though the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms.
  - 9) In MCI patients with a history of depression, long-term SSRI treatment (>4 years) was significantly associated with a delayed progression to Alzheimer's dementia by approximately 3 years, compared with short-term SSRI treatment, treatment with other antidepressants, or no treatment and compared with MCI patients without a history of depression.
- Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology John T O'Brien<sup>1</sup>, Clive Holmes<sup>2</sup>, Matthew Jones<sup>3,4</sup>, et al. Journal of Psychopharmacology, 2017.
- Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression.** Claudia Bartels, PhD, Michael Wagner, PhD., et al. American Journal of Psychiatry, Nov 2017.

---

---

---

---

---

---

---

---

## Pharmacotherapy for Behavioral Disturbances in Dementia: Overview

- There are no FDA-approved treatments for any behavioral disturbances associated with dementia
- Overall approach: "Start low and go slow" and periodic assessment<sup>1</sup>
  - Antidepressants
  - Antipsychotics\*
  - Anticonvulsants
  - Anxiolytics
  - Hypnotics
- Overall, pharmacotherapy has only limited efficacy for neuropsychiatric disorders in dementia<sup>1-3</sup>
  - However, even a small improvement may be beneficial, for caregivers as well as patients
- Appearance of behavioral symptoms may require careful review of all medications, including those for dementia

\*All antipsychotics carry black box warnings relating to elderly patients with dementia.<sup>1,2</sup>  
 1. Zarate CA, et al. *Ann Intern Med*. 2008;148(12):923-932.  
 2. Cummings JL, et al. *Ann Intern Med*. 2008;148(12):923-932.  
 3. Cummings JL, et al. *Ann Intern Med*. 2008;148(12):923-932.  
 4. Cummings JL, et al. *Ann Intern Med*. 2008;148(12):923-932.  
 5. Cummings JL, et al. *Ann Intern Med*. 2008;148(12):923-932.  
 6. Cummings JL, et al. *Ann Intern Med*. 2008;148(12):923-932.  
 7. Cummings JL, et al. *Ann Intern Med*. 2008;148(12):923-932.  
 8. Cummings JL, et al. *Ann Intern Med*. 2008;148(12):923-932.  
 9. Cummings JL, et al. *Ann Intern Med*. 2008;148(12):923-932.  
 10. Cummings JL, et al. *Ann Intern Med*. 2008;148(12):923-932.

## Depression in Long-Term Care

JAMDA

Volume 9, Issue 2, Pages 82-87, February 2008 [Mugdha Thakur, MD](#)

### Affiliations

Mugdha Thakur, MD, [Dan G. Blazer, MD, PhD](#)

- Up to 35% of residents in long-term care facilities may experience either major depression or clinically significant depressive symptoms. These symptoms are often not recognized. Depression is frequently comorbid with other problems that are common in long-term care, such as cognitive impairment, medical illness, and functional impairment. Nevertheless, depression, once diagnosed, can be treated effectively in the nursing home setting. The foundation of treatment is pharmacotherapy, yet other therapeutic approaches, such as exercise and psychological therapies may be of value.

Depression and anxiety are among the most common BPSD and an effective antidepressive therapy in dementia can improve both cognition and affective symptoms as well as other forms of BPSD, such as agitation and aggressiveness.<sup>6,14,106</sup> Tricyclic antidepressants are not recommended because of their anticholinergic adverse events. SSRIs have reasonable tolerability and favourable treatment response. In dementia, SSRIs (specifically citalopram) are as efficacious as atypical antipsychotics for treating agitation.<sup>107</sup> SSRIs can be associated with severe adverse effects such as QT-prolongation and hyponatraemia.

From <<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518961/>>

In MCI patients with a history of depression, long-term SSRI treatment (>4 years) was significantly associated with a delayed progression to Alzheimer's dementia by approximately 3 years, compared with short-term SSRI treatment, treatment with other antidepressants, or no treatment and compared with MCI patients without a history of depression. No differences in CSF biomarker levels were observed between treatment groups. Citalopram was used at 20-30mg/d.

---

---

---

---

---

---

---

---

Mirtazapine...Remeron  
Sleep/appetite 15-30mg  
Mood....30-60mg  
Trazodone...  
Sleep 25-200mg  
Anxiety/depression  
25-50mg, BID, TID, QID

---

---

---

---

---

---

---

---

#### Legal considerations

- Have you advised your patient and their caregiver(s) to seek legal advice with regard to planning for future incapacity?[122](#)
- Are you aware of the state requirements regarding medical fitness to drive for patients with AD?[121](#)
- Are you aware of your legal obligations/appropriate steps to take if you suspect abuse/neglect in the patient or caregiver?[123](#)
- Child Proof the house, guns, sharp utensils, etc over times and possibly get car keys

---

---

---

---

---

---

---

---

**Inadequate Indications:**

Antipsychotic medications in persons with dementia should not be used if the only indication is one or more of the following:

- wandering
- poor self-care
- restlessness
- impaired memory
- mild anxiety
- insomnia
- inattention or indifference to surroundings
- sadness or crying alone that is not related to depression or other psychiatric disorders
- fidgeting
- nervousness
- uncooperativeness (e.g. refusal of or difficulty receiving care).

---

---

---

---

---

---

---

---

First, it is important to state that antipsychotics have not been approved for clinical use in dementia, except for risperidone, at least in some countries.

From  
<<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518961/>>

---

---

---

---

---

---

---

---

Indications to use antipsychotics for patients with dementia include:

\*severe agitation and aggression associated with risk of harm

\*delusions and hallucinations

\*comorbid preexisting mental health conditions (eg, bipolar disorder, schizophrenia, treatment-resistant depression, etc.).

Symptoms that do not usually respond to an antipsychotic include wandering, social withdrawal, shouting, pacing, touching, cognitive defects, and incontinence.<sup>12</sup> These symptoms may respond to interventions such as changes to the environment.

---

---

---

---

---

---

---

---

Table 2

### Psychopharmacologic treatments based on a psychobehavioral metaphor

Symptoms	Medication class
Depressed/anxious: agitated, socially withdrawn, dysphoric, irritable	Antidepressant
Manic: agitated, psychomotor activation, labile affect, rapid speech	Mood stabilizer
Psychotic: agitated, aggressive, delusional, hallucinating	Antipsychotic

Source: Reference 11

### Black box warning

- Increased Mortality in Elderly Patients with Dementia-Related Psychosis  
Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of seventeen placebo controlled trials (modal duration of 10 weeks) in these patients revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10 week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. RISPERDAL® (risperidone) is not approved for the treatment of patients with Dementia-Related Psychosis.





## Schizophrenia or Dementia?

- Dementia Praecox

The term "dementia praecox" was first used in 1891 by [Arnold Pick](#) (1851–1924), a professor of psychiatry at [Charles University in Prague](#).

**Dementia praecox** (a "premature dementia" or "precocious madness") is a disused [psychiatric](#) diagnosis that originally designated a chronic, deteriorating [psychotic disorder](#) characterized by rapid cognitive disintegration, usually beginning in the late teens or early adulthood. Over the years, the term "dementia praecox" was gradually replaced by "[schizophrenia](#)", which remains in [current diagnostic use](#).

If patient has primary schizophrenia, Bipolar DO, etc use standard medication protocols, adjusted for age.

. While it's not part of the diagnostic criteria, they do consider someone's age. The typical age of schizophrenia diagnosis is between late adolescence and the mid-30s. This varies, though, with peak ages ranging from the early- to mid-20s for males and late-20s for females (Are Schizophrenia Symptoms in Males and Females Different?). Further, while it's rare, schizophrenia can be diagnosed as early as childhood and as late as the 40s.

If patient has primary schizophrenia, Bipolar DO, etc use standard medication protocols, adjusted for age.

Clarify Dx...  
 Misperceptions, confusion are not  
 hallucinations!  
 "I have to go to work, pick up my children,  
 fix my husband's dinner, etc."

---

---

---

---

---

---

---

---




---

---

---

---

---

---

---

---

No medications have an indication for use in this population. It is proposed that doses which have been used in completed randomized trials that reflect the best information available about the dose are likely to maximize benefit and minimize risk. On the basis of those trials, reasonable starting doses would be<sup>15-22</sup>:

- quetiapine 25 to 50 mg/d
- risperidone 0.5 to 1 mg/d
- aripiprazole 2 to 10 mg/d
- olanzapine 2.5 to 5 mg/d
- ziprasidone 20 mg/d

The highest doses tested for each of these compounds in randomized clinical trials for this population were: risperidone 2 mg/d, olanzapine 10 mg/d, and aripiprazole 15 mg/d. A wide variety of maximum doses of quetiapine were studied in clinical trials, with a top dose of 200 mg being most common. It is worth noting that doses higher than these have been used for other indications.<sup>15-22</sup>

---

---

---

---

---

---

---

---

Atypical antipsychotics such as risperidone and aripiprazole are among the most often (and probably too often) prescribed drugs in BPSD. They are effective in the treatment of psychotic symptoms, agitation and aggression.<sup>2,14,108,109</sup>

From <<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518961/>>

Most studies and reviews recommend Risperdal as 1<sup>st</sup> choice and either Seroquel or Abilify as a second choice.

Haloperidol may be considered in the treatment of delirium in dementia, but it is not recommended for a different use in dementia. And no longer recommended in Dementia either (twice the level of cardiac complications as Risperdal).

From <<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518961/>>

---

---

---

---

---

---

---

---

While the evidence on the efficacy of quetiapine for BPSD is mixed, it is widely used clinically.<sup>111</sup> Due to its favourable side-effect profile, particularly regarding extrapyramidal signs, quetiapine may be of particular value for BPSD, especially in patients with Parkinsonian features, despite conflicting evidence.<sup>112</sup>

From

<<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518961/>>

Limit use, try 14-21d and try to re-evaluate

---

---

---

---

---

---

---

---

Everything will kill you



so choose something fun

---

---

---

---

---

---

---

---

## MOOD STABILIZERS

Although carbamazepine shows some benefit for agitation in dementia, mood stabilizers are often associated with severe side effects.<sup>2,14,113</sup> Trileptal has similar action to CBZ with fewer side effects. Valproic acid is not recommended. There is some clinical experience and limited evidence for gabapentine and lamotrigine in the treatment of BPSD.

From:

<<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC518961/>>

VPA has freq hepatoenkephalopathy

---

---

---

---

---

---

---

---

ONE WAY TO FIND OUT IF YOU  
ARE OLD IS TO FALL DOWN IN  
FRONT OF A LOT OF PEOPLE. IF  
THEY LAUGH, YOU'RE STILL  
YOUNG. IF THEY PANIC AND  
START RUNNING TO YOU,  
YOU'RE OLD.

---

---

---

---

---

---

---

---

## Benzodiazepines

Evidence for the efficacy of benzodiazepines in BPSD is lacking. Benzodiazepines are associated with sedation, dizziness, falls, worsening cognition, respiratory depression, dependency and paradoxical disinhibition in the elderly. They are thus only recommended for the management of an acute crisis,<sup>6,14</sup> if other methods fail. Their use must be limited in time and they should not be prescribed as hypnotics. SNF prn Bz is 7-14d.

From

<<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC518961/>>

---

---

---

---

---

---

---

---

### Sedative/Hypnotics

Hypnotics such as zopiclone, zolpidem or zaleplone can have similar side-effects as benzodiazepines.<sup>6</sup> They are used for sleep disorders in dementia over a limited period of time and at small doses. Sedative antidepressants such as trazodone seem to improve sleep duration. Melatonin and melatonin receptor agonists can be effective in treating circadian sleep disorders.<sup>34,35</sup>

From  
<<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518961/>>

---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---